Science News
from research organizations

Estrogen receptor-alpha, breast cancer patients and tamoxifen response

Date:
November 26, 2009
Source:
Journal of the National Cancer Institute
Summary:
Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen-receptor-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118.
Share:
         
Total shares:  
FULL STORY

Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen receptor (ER)-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118 (ER-alpha S118-P), according to a brief communication published online November 25 in the Journal of the National Cancer Institute.

Approximately 50% of breast carcinomas are resistant to tamoxifen. Preclinical studies have shown that ER-alpha S118-P is required for response to tamoxifen.

Göran Landberg, M.D., Ph.D., of the Breakthrough Breast Cancer Research Unit, School of Cancer, Enabling Sciences and Technology at the University of Manchester, and colleagues evaluated data from 239 premenopausal patients with breast cancer who participated in a randomized trial of 2 years of adjuvant tamoxifen treatment vs. no systemic treatment. The association between recurrence-free survival and ER-alpha S118-P expression in tumor tissue was investigated.

Researchers found evidence of a statistically significant recurrence-free survival benefit from adjuvant tamoxifen, compared with no systemic treatment, among patients whose tumors had high ER-alpha S118-P expression (23.7 vs. 72.2 recurrences per 1000 person-years) but not among patients whose tumors had low expression (51.0 vs. 57.0 recurrences per 1000 person-years). ER-alpha S118-P was not associated with a benefit among untreated patients.

"Our study highlights the importance of assessing the functionality of a drug target," the authors write. "Future studies are necessary to evaluate whether ER-alpha S118-P expression is associated with tamoxifen response among post-menopausal patients."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Estrogen receptor-alpha, breast cancer patients and tamoxifen response." ScienceDaily. ScienceDaily, 26 November 2009. <www.sciencedaily.com/releases/2009/11/091126083414.htm>.
Journal of the National Cancer Institute. (2009, November 26). Estrogen receptor-alpha, breast cancer patients and tamoxifen response. ScienceDaily. Retrieved April 26, 2015 from www.sciencedaily.com/releases/2009/11/091126083414.htm
Journal of the National Cancer Institute. "Estrogen receptor-alpha, breast cancer patients and tamoxifen response." ScienceDaily. www.sciencedaily.com/releases/2009/11/091126083414.htm (accessed April 26, 2015).

Share This Page:


Health & Medicine News
April 26, 2015

Latest Headlines
updated 12:56 pm ET